Recent studies revealed that branaplam and risdiplam not only reduce Huntingtin protein via PE inclusion but also suppress CAG repeat expansion in HTT exon 1 by modulating PMS1, a known modifier of HD age‐at‐onset [156]. This evidence concerns the gene HTT and Huntington disease.